Compare SOAR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SOAR | JAGX |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | SOAR | JAGX |
|---|---|---|
| Price | $0.56 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 3.1M | ★ 10.5M |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $58,312,000.00 | $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | $0.35 | ★ N/A |
| Revenue Growth | N/A | ★ 12.45 |
| 52 Week Low | $0.41 | $0.64 |
| 52 Week High | $6.48 | $25.75 |
| Indicator | SOAR | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 41.37 |
| Support Level | $0.41 | $0.68 |
| Resistance Level | $0.73 | $0.80 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 39.57 | 5.12 |
Volato Group Inc operates an aircraft ownership program, provides ad-hoc charter flights, sells deposit products, and manages aircraft for owners in the private aviation industry. It offers fractional ownership, aircraft management, jet cards, deposit, and charter programs. The company's fractional programs provides flexible hours and a revenue share for owners in a fleet of HondaJets, optimized for missions of up to four passengers.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.